Jaffary Says AVNR a Buying Opportunity. $ 30 Target. LINK
Avanir sell-off a buying opportunity, says Piper Jaffray
Piper Jaffray attributes last week's 30% sell-off in shares of Avanir to accusations of off-label marketing of Nuedexta and concerns regarding the ongoing patent litigation. Piper views both issues as overblown and says the pullback in shares is a buying opportunity. The firm keeps an Overweight rating on Avanir with a $30 price target.